Cardiogenesis’ Phoenix TMR plus biologic
This article was originally published in The Gray Sheet
Executive SummaryPhoenix gains CE mark approval, enabling a "controlled" European launch, the firm announces Oct. 10. The advanced combination delivery system administers Cardiogenesis' transmyocardial revascularization laser treatment in conjunction with biologic therapy, such as autologous bone marrow stems cells, for advanced coronary artery disease not treatable with bypass surgery. Initial clinical data, along with ongoing research, will help determine "the appropriate regulatory, reimbursement and commercial strategies in the U.S.," the firm states. The combination Ho:YAG laser energy/biologic delivery system also can be used with drugs, according to Cardiogenesis...
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.